Company ProfilePremium

AdAlta Limited

Company Profile Analysis

Ticker: 1AD.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
AdAlta Limited - Company showcase

Year Founded & Workforce

2006

2 Employees

AdAlta Limited logo

AdAlta Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AdAlta Limited Overview

AdAlta is a virtual, clinical-stage Australian biotechnology company that has transformed itself from a single-platform protein-therapeutics discoverer into an "East to West" cell-therapy developer. Its business model is to in-license clinically validated, highly differentiated T-cell therapies for solid cancers from Asian (predominantly Chinese) originators, re-establish their manufacturing in Australia to US FDA standards, run first Western Phase 1 studies under an FDA IND, and then on-license each product to larger biopharmaceutical companies, sharing proceeds with the originator. Its first asset, EW-001 (formerly BZDS1901), is a PD-1-armoured mesothelin CAR-T licensed from Shanghai Cell Therapy Group for all markets outside Greater China, with an FDA pre-IND meeting scheduled for 4 November 2026 (AEST). Legacy i-body assets—Phase 2-ready anti-fibrotic AD-214 and anti-malarial WD-34—are held for partnering. The company is cash-constrained, carries a going-concern qualification and trades as a deep-penny stock.


Company's own description (FY2026 Annual Report)

The FY2026 Annual Report describes AdAlta as a clinical-stage biotechnology business whose principal activity is developing next-generation cellular immunotherapies for solid cancers, together with commercialising protein therapeutics previously discovered on its proprietary i-body® platform. Through the "East to West" strategy, the company states that it integrates Asia's capability in T-cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem, in-licensing clinically de-risked products from Asian originators, investing to establish FDA-regulated manufacturing and early clinical studies, and positioning each product for on-licensing to larger biopharmaceutical companies for registrational studies and commercialisation. Management describes the model as deliberately capital efficient, designed to return investment on each project within three to four years, and replicable across multiple products.

Independent characterisation

In substance, AdAlta is a development-stage asset aggregator and regulatory/manufacturing "translator" rather than a discovery company. Its value-add sits in the middle of the pharmaceutical value chain:

Upstream (sourcing): screening Asian cell-therapy assets that already have human clinical data in solid tumours. AdAlta uses an in-house AI screening agent ("EMU", built on Anthropic's Claude) to produce referenced preliminary due diligence and score candidates against its selection criteria.

Midstream (value creation): technology transfer of manufacturing to an Australian contract manufacturer (Cell Therapies Pty Ltd, Melbourne), FDA pre-IND engagement (with Dark Horse Consulting Group as regulatory adviser), and first-in-Western-patient Phase 1 studies in Australia, exploiting Australia's comparatively fast and cost-efficient clinical-trial environment and R&D Tax Incentive.

Downstream (monetisation): out-licensing or sale of each asset after Phase 1, with AdAlta entitled to 60% of the proceeds of any commercialisation event following Phase 1 completion for EW-001 (FY2026 Annual Report).

The legacy i-body portfolio (AD-214, WD-34) is now a non-core monetisation pool: management is pursuing out-licensing, spin-out, or grant-funded paths and has ceased internal discovery R&D (February 2025).

Revenue model

Revenue typeCurrent status (FY2026)Commentary
Product salesNilNo approved products
Services / collaboration revenueNil in FY2025–FY2026Historical collaboration income (GE Healthcare, Carina Biotech) appears to have ceased
Licensing (out-licensing upfronts/milestones/royalties)Nil to dateTarget monetisation route for AD-214, WD-34 and, post-Phase 1, EW-001
Government grants / tax incentivesA$404,245 R&D Tax Incentive (RDTI) recognised as "other revenue" in FY2026 (FY2025: A$677,010)The sole recurring inflow; at risk from proposed RDTI changes in the 12 May 2026 federal budget
Interest incomeA$73,987 (FY2026)Immaterial

Customer types and end-markets

There are no customers in a commercial sense. Prospective counterparties are (i) large and mid-sized biopharmaceutical companies seeking Western-validated solid-tumour cell therapies (the eventual licensees of EW-001 and successor assets); (ii) fibrosis-focused pharma (IPF, interstitial lung disease, kidney fibrosis) for AD-214; and (iii) global-health funders, defence/travel-medicine stakeholders and vaccine developers for WD-34. End-markets: oncology (mesothelioma and other mesothelin-expressing cancers such as ovarian, pancreatic and some lung cancers), fibrotic disease, and infectious disease (malaria, babesiosis, toxoplasmosis).

Strategy

Stated strategy (themes from FY2026 Annual Report and 2025 AGM)

  1. "East to West" as the key growth driver. The company highlights an "innovation surplus" in Asia—roughly 40% of global cellular immunotherapy developers and 60% of clinical trials are located there—that cannot easily reach Western patients because of data acceptance, transaction cost and supply-chain barriers. AdAlta positions itself as a "force multiplier" that "Westernises" these assets.

  2. In-license → add value → exit → recycle. Capital from each exit is recycled into the next asset; the platform is designed to scale across multiple products using public and private capital.

  3. Disciplined asset selection. Criteria: solid cancers only; engineered T-cell products; first- or best-in-class potential; existing human clinical proof of concept; closed, scalable, low-cost manufacturing (or a clear path to one).

  4. Capital efficiency and asset-level financing. Private financing at AdCella/asset level to fund EW-001 to Phase 1 readout and acquire further assets while limiting parent dilution.

  5. Monetise legacy i-body assets (AD-214, WD-34) via partnering, licensing or spin-out.

  6. AI-augmented operating model. EMU (Claude-based screening agent) and the Oktopi collaboration extend a two-person team's reach; the Board has adopted oversight principles keeping human experts accountable.

The Chair told the 2025 AGM the company was "on the cusp" of creating a regional leader in cellular immunotherapies.

Initiatives announced in the last 24 months

DateInitiativeTypeTarget / status
Apr 2024Creation of AdCella and AdSolis subsidiariesOrganisationalDone
Oct 2024 – Feb 2025Three non-binding CAR-T term sheetsPipeline sourcingOne converted (EW-001)
Feb 2025Cessation of internal discovery R&D; AD-214 partner-onlyCost programDone
2,025Laboratory closure and asset disposalCost programDone (A$0.11m proceeds)
Oct 2025 – Apr 2026CEO and NED pay suspensionCost programEnded 30 Apr 2026
Jan 2026DCA with SHcell for BZDS1901/EW-001In-licensingInitial obligations met
Mar 2026EW-001 Clinical Advisory Board expansionClinicalDone
Apr 2026First Work Order with Cell Therapies Pty LtdManufacturingTech transfer underway; first runs 2H CY2026
Apr 2026MoU with Cell Therapies and Oribiotech (IRO® automated platform)Manufacturing innovationDeployment targeted CY2027; 10–50x throughput, 30–50% potential cost saving
May 2026Dark Horse Consulting engaged as regulatory advisersRegulatoryPre-IND 4 Nov 2026
Jul 2026Oktopi AI collaborationDigital/AIActive
Jul 2026ISCT ANZ 2026 oral presentation and posterScientific visibilityDone
2026–2027One to two further assets under option or licencePipelinePending
2026–2027WD-34 grant applications / possible spin-outMonetisationPending

Medium-term targets / guidance

TimingMilestone
2H CY2026First Australian manufacturing runs of EW-001 at CTPL
2H CY2026US FDA pre-IND meeting (confirmed 4 Nov 2026 AEST)
CY2026–2027One to two further assets secured under option/licence
CY2026–2027Extended IIT readouts from China
CY2027Deployment of IRO® automated platform at CTPL
2H CY2027First patient dosed in Australian Phase 1 of EW-001
Not forecastableAD-214 / WD-34 partnering, licensing or spin-out

No financial guidance is provided (directors withhold likely-developments disclosure as commercially prejudicial). Operational milestone guidance (FY2026 Annual Report):

ESG commitments: formal ESG governance model "being developed"; no quantified targets.

Products & Services

Cellular immunotherapies (AdCella)

AttributeDetail
ModalityAutologous CAR-T cell therapy (patient's own T cells engineered ex vivo)
TargetMesothelin (MSLN), highly expressed in mesothelioma and >10 other cancers
DifferentiationFirst MSLN CAR-T designed to secrete PD-1-blocking molecules ("armoured"), protecting both infused CAR-T cells and endogenous T cells from tumour immunosuppression; binding tuned to activate only where MSLN is densely expressed (to spare healthy tissue)
ManufacturingNon-viral (transposase-based) process; under two days versus ~nine days for many traditional CAR-Ts; no expensive viral vectors; third-generation faster/lower-cost process being transferred to Cell Therapies Pty Ltd (Melbourne); future automation via Oribiotech IRO® platform; target commercial cost of goods <US$50,000 per patient dose
OriginatorShanghai Cell Therapy Group Co Ltd (SHcell), China
RightsExclusive licence to develop and commercialise outside Greater China (DCA, 2 Jan 2026); exclusive or non-exclusive licences to seven patent families
EconomicsUS$2.0m paid in two milestones (completed by mid-2026); AdAlta receives 60% of proceeds of any commercialisation event after Phase 1; AdCella estimated in January 2026 it could invest A$22–31 million over four years to reach end of Phase 1 (inclusive of upfront and milestones)
Clinical data (China IITs, as at July–Oct 2026)36 patients across three investigator-initiated trials; at higher doses up to 50% overall response rate and up to 20% complete response rate in second-line-plus advanced mesothelioma; median OS not reached in current-generation process; earlier generation achieved >25 months median OS; one complete responder completed the two-year study assessment without recurrence, second complete responder past one year
Comparator benchmarks (cited by company)Second-line standard therapies: ORR 11–29%, CR almost never, median survival 8–10 months (CONFIRM, CheckMate-743 references)
StagePre-IND (Western); FDA pre-IND meeting 4 Nov 2026 AEST; first Australian manufacturing runs targeted 2H CY2026; first Australian Phase 1 patient targeted 2H CY2027
Target customerLarge biopharma licensee post-Phase 1
PricingNot disclosed (pre-commercial)
Market sizing (company)Mesothelioma drugs market forecast US$12.2bn by 2034; EW-001 addressable advanced-mesothelioma market ~US$4.2bn before other MSLN+ cancers; >35,000 new mesothelioma cases and >29,000 deaths annually

EW-001 (formerly BZDS1901)

Pipeline candidates (unnamed): additional CAR-T/engineered T-cell assets in due diligence; stated aspiration to progress one new asset into the clinic each year and secure one to two further assets under option or licence in CY2026–2027. Three non-binding term sheets had been executed by February 2025; none besides EW-001 has been publicly converted to a definitive licence.

i-body® enabled protein therapeutics

AttributeDetail
ModalityFirst-in-class i-body Fc-fusion protein
TargetCXCR4 (G-protein-coupled receptor)
IndicationsIdiopathic pulmonary fibrosis (IPF), interstitial lung disease, kidney fibrosis; historical exploration of eye fibrosis and inhaled formulation
Clinical statusTwo successful Phase I studies (single ascending dose IV in healthy volunteers; Phase I extension establishing tolerability of planned Phase 2 dose of 10 mg/kg IV every two weeks); low-level anti-drug antibodies without PK/PD impact; declared Phase 2-ready
IPComposition-of-matter patents granted in Australia, US, Europe, China, Japan, India, Singapore and Canada, expiring 8 January 2036; method-of-treatment applications could extend to 2043
Commercial pathOut-licence (lung and/or kidney) or spin-out financing of Phase 2; most recent inbound interest focused on kidney fibrosis
Competitive contextBoehringer Ingelheim's nerandomilast (Jascayd) approved by FDA for IPF (Oct 2025) and progressive pulmonary fibrosis (Dec 2025), per company
AttributeDetail
Modalityi-body (discovery stage), discovered with La Trobe University
TargetConserved region of AMA1 (apical membrane antigen 1)
ProfilePan-species recognition of Plasmodium species plus Babesia and Toxoplasma; high-potency inhibition of parasite invasion
Potential usesLong-acting single-dose prophylaxis (travellers, military), seasonal malaria chemoprevention for children, antigen generation for vaccines
StatusSeeking grant/third-party funding for format optimisation and pre-clinical proof of concept; possible dedicated spin-out; patent applications lodged

AD-214

WD-34

Legacy / discontinued programs: GE Healthcare granzyme B i-body PET imaging agents (collaboration active through at least FY2023; current status not publicly disclosed); Carina Biotech i-body-directed CAR-T collaboration (five solid-tumour antigens; current status not publicly disclosed); internal i-body discovery (ceased February 2025).

Enabling capabilities

CapabilityDescription
EMUIn-house AI agent built on Anthropic's Claude for referenced due diligence and asset scoring
Oktopi collaboration (July 2026)AI-enabled platform to peer-review development plans and expert decisions
i-body platformHuman protein scaffold libraries (>2 billion compounds at IPO) mimicking shark single-domain antibodies

Financial Narrative

Blank cells = not publicly disclosed in sources reviewed or not meaningful.

Income statement

Gross profit, operating income, EBITDA and pre-tax income margins are not meaningful in the absence of revenue. EBITDA ≈ operating loss given negligible depreciation (FY2026 depreciation nil; FY2025 A$0.085m). Pre-tax income equals net loss (no tax expense; ~A$23.8m of unrecognised revenue tax losses at 30 June 2026). Revenue CAGR: not meaningful.

Balance sheet

Notes: FY2024 long-term debt (A$1.321m) per InvestSMART relates to the NLSC/Meurs institutional investment liability; FY2024 also carried the Treasury Corporation of Victoria R&D loan (A$1.40m, repaid October 2024). FY2026 "other current liabilities" of A$0.82m are share-application monies (A$0.795m for shares requiring the 15 June 2026 EGM approval, issued 2 July 2026, plus A$25k to be refunded) and are not debt.

Cash flow

FY2026 equity raised gross = A$4.512m share proceeds + A$0.820m share monies requiring approval. FY2025 investing inflow reflects disposal of laboratory plant and equipment (A$0.110m) after laboratory closure.

Ratios

ROE, ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful (negative/near-zero equity, no revenue, no invested operating capital). ROA computed on average total assets. FY2025 debt/equity is undefined due to negative equity (−A$0.598m).

Commentary on trends, inflections and drivers

Loss trajectory. Net losses have been remarkably stable in the A$4.5–6.1 million band across five years, but the composition has changed fundamentally. FY2022–FY2024 losses funded an in-house laboratory, AD-214 clinical studies and platform discovery; FY2026's A$4.68 million loss is dominated by a single non-recurring item—A$2.858 million of EW-001 licence/milestone payments to SHcell—with underlying operating costs collapsing. Corporate administration (external) halved from A$2.12m to A$1.02m, and employee costs across R&D and admin fell from A$1.30m to A$0.26m, reflecting laboratory closure, a two-person permanent workforce, and the suspension of CEO pay (November 2025–April 2026) and non-executive director fees (October 2025–April 2026).

Liquidity is the binding constraint. Cash has declined monotonically from A$8.66m (FY2022) to A$1.28m (FY2026). The FY2026 cash balance was almost unchanged from FY2025 only because A$5.3m of equity was raised across three placements. With the US$2.0m DCA commitment now satisfied, the run-rate burn should fall, but the company's own January 2026 estimate of A$22–31m to take EW-001 through Phase 1 vastly exceeds its balance sheet. Management's intended solution is asset-level (AdCella) private financing to limit dilution at the listed parent.

Balance sheet clean-up. FY2026 saw the elimination of all interest-bearing and convertible obligations: the Radium Capital RDTI advance (16% p.a.) was repaid in December 2025, and the NLSC/Meurs institutional investment liability (A$1.38m at FY2025) was extinguished through A$1.201m of conversions into 667 million shares and A$0.407m of cash repayment. This restored positive equity (A$0.37m) and net tangible assets per share of 0.01–0.02 cents, but at the cost of severe dilution.

Dilution. Shares on issue rose from ~596 million (FY2024) to ~1,071 million (FY2025) to ~2,976 million (FY2026) and ~3,212 million after the July 2026 issue—a more than fivefold increase in two years—while ~1.08 billion A$0.01 listed options overhang the register. Weighted-average shares tripled in FY2026, which is why EPS improved from −0.69c to −0.23c despite a larger loss.

RDTI dependence. RDTI refunds historically funded a third or more of annual burn (A$2.08m for FY2022, A$2.35m for FY2023, A$1.77m for FY2024). The FY2026 receivable is only A$0.22m because most spend was offshore licence payments (an Overseas Finding application is pending which could increase it). The 12 May 2026 federal budget proposals could materially reduce and delay future RDTI benefits, per the Annual Report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

Business unit (management view)Legal vehicleContentsStatus

"East to West" cellular immunotherapies

AdCella Pty Ltd (subsidiary; created April 2024)

EW-001 (formerly BZDS1901) mesothelin CAR-T; pipeline of further in-licensing candidates in due diligence

Core growth driver

i-body® enabled assets

AdAlta Limited / AdSolis Pty Ltd (created April 2024)

AD-214 (fibrosis), WD-34 (malaria), residual i-body IP

Partnering / spin-out only

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Revenue and other income - single segment (AUD Mn)

1.7380.6960.478

Of which RDTI income (AUD Mn)

—0.6770.404

Loss before tax - single segment (AUD Mn)

-5.381-4.502-4.684

YoY change in loss (%)

10.9-16.34.0

Revenue by Segment

MetricFY2025FY2026

R&D expense external (AUD Mn)

1.3363.212

R&D employee benefits (AUD Mn)

0.8600.124

Corporate admin external (AUD Mn)

2.1191.018

Corporate admin employee benefits (AUD Mn)

0.4440.137

Patent and legal (AUD Mn)

0.2200.275

Finance costs (AUD Mn)

0.0620.291

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from customers (AUD Mn)

———00

Revenue and other income incl RDTI (AUD Mn)

2.7543.4691.7380.6960.478

Total expenses (AUD Mn)

———5.1985.162

R&D expense total (AUD Mn)

———2.1963.336

Net loss after tax (AUD Mn)

-6.061-4.851-5.381-4.502-4.684

Basic EPS (AUD cents)

—-1.3-0.9-0.69-0.23

Diluted EPS (AUD cents)

—-1.3-0.9-0.69-0.23

Dividends per share (AUD cents)

00000

Weighted avg shares (M)

———653.12,047.7

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

8.6614.7903.1331.3061.284

Trade and other receivables (AUD Mn)

———0.8360.437

Total assets (AUD Mn)

———2.1421.722

Short-term debt (AUD Mn)

———0.4470

Long-term debt and financial liabilities (AUD Mn)

——1.3211.3760

Total debt (AUD Mn)

———1.8230

Net debt (AUD Mn)

———0.517-1.284

Total liabilities (AUD Mn)

———2.7401.351

Shareholders equity (AUD Mn)

—1.92.030-0.5980.370

Goodwill and intangibles (AUD Mn)

00000

Working capital (AUD Mn)

———0.8050.370

Accumulated losses (AUD Mn)

——47.52052.02356.706

Shares on issue year end (M)

——595.61,071.32,975.9

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-4.089-5.132-5.260-2.937-4.440

Investing cash flow (AUD Mn)

-0.025-0.002-0.0620.1100

Capex (AUD Mn)

0.0250.0020.06200

Free cash flow (AUD Mn)

-4.114-5.134-5.322-2.937-4.440

Financing cash flow (AUD Mn)

7.0231.2673.6660.9994.419

Equity raised gross (AUD Mn)

———1.2845.332

RDTI cash received in year (AUD Mn)

———1.7750.934

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Financial Ratios (x) and Returns & Leverage Ratios (%)

MetricFY2025FY2026

Current ratio (x)

1.601.27

Debt to equity (x)

—0

ROA (%)

-233-242

Cash burn per quarter avg (AUD Mn)

0.731.11

Revenue by Region

MetricFY2024FY2025FY2026

Australia revenue and other income (AUD Mn)

1.7380.6960.478

Americas revenue (AUD Mn)

000

EMEA revenue (AUD Mn)

000

Asia ex-Australia revenue (AUD Mn)

000

Capital Markets

ItemDetail

Latest verified price

A$0.003–0.004 (InvestSMART, June–July 2026; announcement-date prices through Q3 2026 at ~A$0.004)

52-week range

A$0.0017 – A$0.008 (Stocklight)

Market cap (approx.)

A$10–13m on ~3.21bn shares

Listed options

1ADO: ~1.08bn, A$0.01 exercise, expiry 3 Jun 2028 (deeply out of the money at ~2.5–3x current price)

Index membership

None identified

Dividend history / policy

No dividends ever paid; none expected

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

No debt outstanding at 30 June 2026

Capital Markets — Price change

Metric1-year3-year

Price change (%)

Approximately flat to down (A$0.003–0.005 range through 2025–2026)

Approximately −80% to −85% (≈A$0.02 in late 2023 to ≈A$0.003–0.004)

Share Count (M) and Margin Analysis (%)

MetricFY2024FY2025FY2026

Shares on issue year end (M)

595.61,071.32,975.9

Annual shareholder return (%)

8.4-90.8—

Equity issued for cash in year (AUD Mn)

—1.2844.512

Valuation Multiples

MultipleAdAltaComment

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

No revenue

P/B

~27–35x

Market cap A$10–13m vs equity A$0.37m (FY2026); not meaningful given tiny book

EV (approx.)

~A$9–12m

Market cap less ~A$1.3m cash, zero debt

Analyst Conclusions

Management guidance

No financial guidance. Operational guidance: first Australian EW-001 manufacturing runs and FDA pre-IND meeting in 2H CY2026 (pre-IND confirmed 4 Nov 2026 AEST, minutes 2–4 weeks later); one to two additional assets in CY2026–2027; IRO® deployment CY2027; first Australian Phase 1 patient 2H CY2027. Consensus growth expectations: none available.

Bull case

  1. Differentiated clinical signal: complete responses (up to 20%) and durable two-year disease-free survival in a refractory solid tumour are rare; if replicated in an FDA-grade Australian Phase 1, EW-001 could command a meaningful licence deal, of which AdAlta retains 60% of proceeds.

  2. Low-cost model with optionality: a two-person, debt-free virtual company with an EV of roughly A$10m holds a pre-IND CAR-T, a Phase 2-ready anti-fibrotic with patents to 2036+, and a novel anti-malarial—each partnering event could rerate the stock.

  3. Manufacturing moat: a non-viral <2-day process plus automation targeting <US$50k COGS addresses the main commercial objection to CAR-T, enhancing attractiveness to big pharma.

Bear case

  1. Funding gap: A$1.28m cash versus A$22–31m to reach Phase 1 readout; absent asset-level financing, further heavily dilutive raises at sub-cent prices are likely, on top of ~1.08bn options.

  2. Data fragility: 36 patients in non-randomised Chinese IITs; the October 2026 update revealed progression in two of five recently followed patients; FDA may require substantial additional work.

  3. Execution and geopolitical concentration: dependence on a single Chinese originator (approvals via JDC, materials supply) and a single CDMO amid US–China tensions, with only two employees and a four-person board.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 2026September-quarter 4C: cash position and burn
4 Nov 2026FDA pre-IND meeting; minutes ~late Nov–Dec 2026
2H CY2026First CTPL manufacturing runs and comparability data
Nov 20262026 AGM (possible capital structure resolutions, e.g., consolidation or placement capacity)
Q1 CY2027Next IIT assessments (second CR at 18 months; stable-disease patient)
CY2026–2027AdCella asset-level financing; new asset in-licence
Feb 2027H1 FY2027 report
Any timeAD-214 / WD-34 partnering; RDTI legislative outcome; Hainan special-access patient treatment

Analyst verdict

AdAlta in October 2026 is a fundamentally different company from the i-body discovery platform that listed in 2016. Management has executed a disciplined, if painful, pivot: it shut the laboratory, cut fixed costs to a two-person core, retired every interest-bearing and convertible liability, and converted a strategic thesis—bringing Asian cell-therapy innovation through Western regulatory and manufacturing pathways—into a signed, fully paid-up licence for a genuinely interesting asset. EW-001's complete responses and two-year disease-free survival in relapsed mesothelioma are the kind of signal that cell-therapy business-development teams notice, and its non-viral, rapid manufacturing process speaks directly to the economics that have constrained CAR-T commercially. The FDA's acceptance of a pre-IND meeting within nine months of licensing is tangible evidence that the "East to West" machinery works.

The problem is not the strategy but the balance sheet. With A$1.28 million of cash at year-end, a going-concern qualification for three consecutive years, more than 3.2 billion shares on issue and over a billion options overhanging the register, the listed entity has limited capacity to fund a program it has itself costed at A$22–31 million. Value accretion for existing shareholders therefore depends heavily on securing non-dilutive or asset-level capital (AdCella financing, AD-214 licensing, grants) and on a constructive FDA outcome on 4 November. The October update showing progression in two recently followed patients is a reminder that the clinical dataset is small and immature.

On balance, AdAlta is a high-risk, binary, catalyst-driven micro-cap. The scientific and strategic logic is credible and management execution in 2026 has been on schedule, but the probability-weighted outcome for equity holders is dominated by financing terms. Investors should treat the stock as a speculative option on EW-001's Western translation, with the FDA minutes and the next financing structure as the decisive near-term signals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground / educationIndependence

Dr Paul MacLeman

Non-Executive Chair (formerly Executive Chair)

16 Apr 2015

35 years in life sciences; former CEO/MD IDT Australia (2013–2017), CEO Genetic Technologies (2009–2012), COO Imugene, Executive Chairman Island Pharmaceuticals; Chair of Pharmaceutical Manufacturing Industry Reference Committee. BVSc (Sydney), MBA (Macquarie GSM), FAICD

Non-executive; long tenure (>11 years) may challenge independence under ASX Principles

Dr Timothy Oldham

CEO & Managing Director

Board 8 Oct 2019

Former CEO/MD Cell Therapies Pty Ltd; President Asia Pacific, Hospira; senior roles at Mayne Pharma; McKinsey engagement manager; Executive Leader Tijan Ventures. NED Acrux (ASX:ACR); Chair Skin2Neuron. BSc(Hons), LLB(Hons), PhD

Executive

Ms Michelle Burke

Non-Executive Director; Chair of Remuneration & Nomination Committee

20 Nov 2024

25 years pharma/biotech commercial leadership (Bristol-Myers Squibb, SmithKline Beecham); industry nominee on PBAC; Chair and NED of Cell Therapies Pty Ltd; NED Olivia Newton-John Cancer Research Institute; past Chair AusBiotech. BSc(Hons), GAICD

Non-executive; potential conflict given Cell Therapies is AdAlta's contract manufacturer

Mr Fadi Diab

Non-Executive Director

18 Mar 2026

10 years in financial institutions, technology transformation and IR; MD Phoenix Global Investments; NED Balkan Mining & Minerals (BMM), Simble Solutions (SIS); former NED Lithium Universe, Advance Metals. B.Bus (Western Sydney), Master of Business Management (UTS)

Non-executive

Dr David Fuller

Former NED

22 Jul 2020 – 17 Apr 2026

MBBS, BPharm(Hons)

Resigned

Directors' Remuneration

ItemDetail

Board size

4 (3 NEDs + CEO) at 30 June 2026

Chair / CEO separation

Yes (separate individuals)

Committees

Remuneration & Nomination (Burke – Chair, MacLeman, Diab); Audit & Risk (composition per Corporate Governance Statement; all NEDs invited)

FY2026 meetings

Board 10; Rem & Nom 2; Audit & Risk 1

Gender

1 of 3 NEDs female; both permanent employees male

NED fee pool

A$350,000 approved; current fees A$75,000 (Chair), A$50,000 (NEDs); no committee fees

2025 AGM remuneration report vote

98% in favour

Directors' Remuneration by Name

NameCash salary/fees (AUD)Super (AUD)Share-based (AUD)Total earned (AUD)

Dr Timothy Oldham (CEO & MD)

177,82513,67910,468201,972

Dr Paul MacLeman (Chair)

25,8935,3573,38334,633

Ms Michelle Burke

17,2623,571020,833

Mr Fadi Diab

8,333008,333

Dr David Fuller (resigned)

12,50002,11414,614

Total KMP

241,813

22,607

15,965

280,385

Directors' Shareholdings

DirectorOrdinary sharesUnlisted optionsListed options (1ADO)

Dr Timothy Oldham

17,265,4156,357,1955,833,333

Dr Paul MacLeman

544,0422,800,00035,536

Ms Michelle Burke

000

Mr Fadi Diab

000

Major Shareholders

HolderShares% at notice date

Stuart Morris (and associated entities)

166,108,38814.92

HSBC Custody Nominees (Australia) Limited

92,345,3648.30

Chunyan Niu

66,666,6675.99

Competitive Landscape

Key Competitors

CompetitorSegmentRelevance / positioning vs AdAlta

CARsgen Therapeutics (China/HK-listed)

Solid-tumour CAR-T

Chinese CAR-T leader with solid-tumour programs; a reference point for the first solid-tumour CAR-T approvals in China

Adaptimmune / former TCR2 Therapeutics (gavo-cel)

Mesothelin-targeted T-cell therapy

Historical MSLN TCR-fusion program in mesothelioma; demonstrates target validity and also development risk

Atara Biotherapeutics

Mesothelin CAR-T (allogeneic/armoured)

Prior MSLN CAR-T programs

Memorial Sloan Kettering-derived academic MSLN CAR-T programs

Mesothelioma CAR-T

Academic competition for mesothelioma trial patients

Carina Biotech (private, Adelaide)

Solid-tumour CAR-T

Former AdAlta collaborator; Australian competitor for capital and clinical sites

Chimeric Therapeutics (ASX: CHM)

Solid-tumour CAR-T

ASX peer competing for the same retail/biotech capital pool

Imugene (ASX: IMU)

CAR-T (azer-cel, onCARlytics)

ASX peer in cell therapy

Prescient Therapeutics (ASX: PTX)

OmniCAR / CellPryme platforms

ASX peer

Arovella Therapeutics (ASX: ALA)

iNKT cell therapy

ASX peer

Western "NewCo" in-licensors of Chinese assets (numerous US-based, venture-backed)

In-licensing

Compete for the best Chinese assets with deeper capital

Large pharma (e.g., AstraZeneca, BMS, Novartis)

Direct China in-licensing

Can buy assets directly, bypassing intermediaries

Boehringer Ingelheim (nintedanib; nerandomilast/Jascayd)

IPF / PPF

Incumbent standards of care competing with AD-214

Roche (pirfenidone)

IPF

Incumbent standard of care

Bristol Myers Squibb (admilparant, LPA1 antagonist)

IPF pipeline

Late-stage competitor

GSK / Sanofi malaria franchises; long-acting monoclonal antibody programs (e.g., NIH-derived L9LS)

Malaria prophylaxis

Competing approaches to WD-34

Peer Comparison FY2026

MetricAdAlta FY2026Peer comparison

Revenue

Nil

Most ASX cell-therapy peers also pre-revenue

Net loss (AUD Mn)

4.68—

Cash (AUD Mn)

1.28—

R&D intensity

n/m

n/m

Market cap (AUD Mn, approx.)

10–13

—

Company Snapshot

2

Employees

2006

Founded

Hawthorn East, Australia

Headquarters

SWOT Analysis

Strengths

  • Rare complete responses: up to 20% CR and 50% ORR at higher doses in second-line-plus mesothelioma across China IITs (FY2026 AR; Aug 2026 announcements), versus 11–29% ORR and near-zero CR for standard second-line therapy.
  • Durability signal: first complete responder reached the two-year protocol endpoint with no recurrence (5 Aug & 5 Oct 2026 announcements).
  • Manufacturing economics: <2-day non-viral process vs ~9 days for traditional CAR-T; target COGS <US$50k/dose (FY2026 AR).
  • Regulatory momentum: FDA accepted pre-IND request; meeting 4 Nov 2026 AEST (23 Sep 2026 announcement).
  • Clean balance sheet: zero borrowings and no convertible liabilities at 30 June 2026 vs A$1.82m debt at 30 June 2025 (FY2026 AR).
  • Strong IP on legacy asset: AD-214 composition-of-matter patents across eight jurisdictions to 2036 (FY2026 AR).
  • Ultra-lean cost base: two permanent employees; KMP compensation A$0.28m (FY2026 AR).

Weaknesses

  • Cash of A$1.28m at 30 June 2026 against a FY2026 operating outflow of A$4.44m (FY2026 AR).
  • Going-concern material uncertainty in FY2024, FY2025 and FY2026 audit opinions.
  • Severe dilution: shares rose from 595.6m (FY2024) to ~3,212m (July 2026); ~1.08bn listed options outstanding.
  • Single clinical asset; small, non-randomised, ex-US data set (36 patients) with two of five recently followed patients progressing (5 Oct 2026).
  • Thin governance: board of four; Chair tenure >11 years; NED Michelle Burke chairs the company's contract manufacturer (FY2026 AR).
  • Accumulated losses of A$56.7m with no revenue in FY2025–FY2026.
  • No legacy-asset monetisation despite AD-214 being Phase 2-ready since early 2024.

Opportunities

  • Post-Phase 1 exit: 60% of commercialisation proceeds on EW-001 (FY2026 AR).
  • Label expansion into >10 other MSLN-expressing cancers.
  • Pipeline scaling: one to two additional assets targeted in CY2026–2027; additional candidates in due diligence.
  • Asset-level (AdCella) financing to access international investors without parent dilution.
  • AD-214 kidney-fibrosis licensing, aligned with metabolic/diabetic kidney disease interest (FY2026 AR).
  • Automation via Oribiotech IRO®: 10–50x throughput, 30–50% cost savings (FY2026 AR).
  • WD-34 spin-out / non-dilutive grants.

Threats

  • RDTI reform from the 12 May 2026 federal budget could materially reduce and delay refunds (FY2026 AR risk factor e).
  • US–China trade and biosecurity restrictions (FY2026 AR general risk b).
  • FDA may not accept China IIT data, requiring additional non-clinical work and delaying Phase 1 beyond 2H CY2027.
  • Competition for Asian assets from better-capitalised NewCos and big pharma.
  • MSLN on-target/off-tumour toxicity and CAR-T safety events in a Western Phase 1.
  • Capital-market access: deep-penny pricing (A$0.003–0.005) limits raise sizes; potential share consolidation needed.
  • Partner dependency on SHcell (materials supply, data, JDC approvals) and CTPL.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jun 2025Renounceable rights issue with 1ADO options; CEO subscribes ~11.7m shares, Chair ~71kRecapitalisation; insider support
30 Jun 2025NED Iain Ross resignsBoard contraction
27 Aug 2025FY2025 results: loss A$4.50m (−16.3%); NTA −0.1c; going-concern uncertaintyNegative equity
Oct 2025A$1.6m placement at A$0.003 (20% premium) with 1-for-2 optionsFunding
28 Oct 2025CEO buys 2.5m shares on marketInsider confidence
Oct 2025NED fees suspended (to Apr 2026); CEO pay suspended from Nov 2025Cash preservation
Nov 20252025 AGM: Chair describes company as on the cusp of transformation; remuneration report >98% supportStrategic messaging
4 Dec 2025FY2025 RDTI refund (~A$0.78m) received; Radium facility repaidDebt-free
2 Jan 2026DCA with SHcell for BZDS1901Transformational licensing
13 Jan 2026A$1.2m placement at A$0.005; investor webinarFunding
21 Jan 2026Additional FY2025 RDTI receipt; manufacturing scalability focusCash
~Jan–Mar 2026First US$1m milestone to SHcell paidRights maintained
4 Mar 2026AdCella expands Clinical Advisory Board (Pavlakis, Shackleton)Clinical credibility
18 Mar 2026Fadi Diab joins BoardIR/capital markets
20 Mar 2026AD-214 Canadian patent grantedIP
27 Mar 2026First JDC with SHcell; potential six-month acceleration of tech transfer; Cohort 1 dosing complete in ChinaExecution
1 Apr 2026BZDS1901 clinical updateData
17 Apr 2026Dr David Fuller resignsBoard contraction
Apr 2026Automated manufacturing MoU (CTPL / Oribiotech)Manufacturing
29 Apr 2026BZDS1901 manufacturing agreement with CTPLManufacturing
30 Apr 2026Trading haltCapital raise
4 May 2026A$2.5m placement at A$0.004 (62 Capital)Funding
12 May 2026Federal budget proposes RDTI changes (flagged as risk)Policy headwind
25 May 2026Regulatory advisers (Dark Horse) appointed; 1ADO options prospectusRegulatory
9 Jun 2026Confirmation of prospectus offer resultsCapital
15 Jun 2026EGM approves A$0.8m trancheGovernance
Jun 2026Second US$1m milestone paid; initial DCA obligations fully met; world's first solid-tumour CAR-T approval in China cited as external validationRights secured
2 Jul 2026236.25m shares and 235m options issuedDilution
Jul 2026Oktopi AI collaboration; June-quarter 4CAI / reporting
20 Jul 2026ISCT ANZ 2026 oral presentation and posterScientific profile
5 Aug 2026Two-year survival milestone for first complete responderDurability signal
10 Aug 2026All five patients on study in March alive as of July; higher-dose cohort ORR 50%Dose-response signal
21 Aug 2026FY2026 Annual Report: loss A$4.68m, cash A$1.28m, going-concern uncertainty; auditor Dry KirknessResults
2 Sep 2026SHcell to supply BZDS1901 under Hainan Boao Lecheng special accessReal-world evidence (China)
23 Sep 2026FDA accepts pre-IND meeting request (4 Nov 2026 AEST)Regulatory milestone
5 Oct 2026JDC approves FDA briefing pack (submitted) and tech-transfer plan; patient follow-up update: two patients progressed, one CR completed study, two remain on studyGovernance + data nuance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: R&D expense external rose from AUD 1.3 Mn in FY2025 to AUD 3.2 Mn in FY2026.
AdAlta Limited — Revenue by Segment
Series (AUD Mn)FY2025FY2026
R&D expense external1.33.2
R&D employee benefits0.90.1
Corporate admin external2.11
Corporate admin employee benefits0.40.1
Patent and legal0.20.3
Finance costs0.10.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. AdAlta Limited Annual Report for the year ended 30 June 2026 (21 Aug 2026) (investorpa.com)
  2. AdAlta Appendix 4E FY2025 (27 Aug 2025) (announcements.asx.com.au)
  3. ASX announcement, FDA accepts pre-IND meeting request (23 Sep 2026) (announcements.asx.com.au)
  4. ASX announcement, JDC approves FDA briefing pack and tech-transfer plan (5 Oct 2026) (announcements.asx.com.au)
  5. ASX announcement, Hainan special access (2 Sep 2026) (announcements.asx.com.au)
  6. ASX announcements, EW-001 survival updates (5 & 10 Aug 2026) · announcements.asx.com.au
  7. ISCT ANZ 2026 presentation (20 Jul 2026) (bulletin.webull.com)
  8. June Quarter 2026 4C summary (investorhub.adalta.com.au)
  9. Second BZDS1901 milestone paid (investorhub.adalta.com.au)
  10. DCA with SHcell (2 Jan 2026) · BioSpectrum Asia coverage
  11. January 2026 placement (announcements.asx.com.au)
  12. First JDC meeting (27 Mar 2026) (announcements.asx.com.au)
  13. AD-214 Canadian patent (20 Mar 2026) (announcements.asx.com.au)
  14. InvestSMART announcement summaries and security page · investsmart.com.au
  15. Stocklight announcement list (stocklight.com)
  16. Stoxray historical financials (stoxray.com)
  17. Quartr H2 2026 summary (quartr.com)
  18. Biotech Dispatch (2025 AGM; Fadi Diab appointment; survival signal) (biotechdispatch.com.au)
  19. BioMelbourne, "East to West" prioritised (10 Feb 2025) (biomelbourne.org)
  20. Q1 FY2025 quarterly (24 Oct 2024) (announcements.asx.com.au)
  21. FY2024 RDTI refund (4 Oct 2024) (announcements.asx.com.au)
  22. Half-year reports H1 FY2023 and H1 FY2024 · announcements.asx.com.au
  23. AdAlta board page (adalta.com.au)
  24. CB Insights profile (founding, IPO date) (cbinsights.com)
  25. AdAlta IPO fact sheet (2016) (adalta.com.au)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.